Not Tagged
effector therapeutics
['breast', '$eftr']
top perf. biotech stocks 6/6/23 (mcap &gt;$50 mil.): 1. $eftr +37.6%, +160% since may 25 release with #asco2023 data showing 26% partial response for triplet combo in heavily pretreated er+ metastatic breast cancer, median price target $7.38 (+439%) 
Biotech stock analyst. Editor of Biotech Millionaire at Mauldin Economics. Tweets and opinions are not investment advice.